Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

Transmission studies have suggested that an optimal human immunodeficiency virus type 1 (HIV-1) vaccine should induce both neutralizing antibodies and cytolytic T cells to eliminate free virus and infected cells. A phase I trial in healthy HIV-1-seronegative persons was conducted with a combination...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Cooney, E L, McElrath, M J, Corey, L, Hu, S L, Collier, A C, Arditti, D, Hoffman, M, Coombs, R W, Smith, G E, Greenberg, P D
Format: Artigo
Langue:Inglês
Publié: 1993
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC45984/
https://ncbi.nlm.nih.gov/pubmed/8446603
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires